Xilio Therapeutics, Inc.
XLO
$0.70
-$0.0002-0.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.92% | -0.05% | -15.70% | -16.98% | -21.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.32% | -1.70% | -15.34% | -29.70% | -21.74% |
| Operating Income | 24.83% | 14.73% | 27.05% | 29.70% | 21.74% |
| Income Before Tax | 25.84% | 16.29% | 28.05% | 24.04% | 21.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.84% | 16.29% | 28.05% | 24.04% | 21.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.84% | 16.29% | 28.05% | 24.04% | 21.41% |
| EBIT | 24.83% | 14.73% | 27.05% | 29.70% | 21.74% |
| EBITDA | 25.04% | 14.67% | 27.49% | 30.10% | 22.03% |
| EPS Basic | 68.44% | 63.70% | 55.04% | 25.34% | 21.82% |
| Normalized Basic EPS | 68.43% | 63.58% | 55.13% | 29.44% | 21.83% |
| EPS Diluted | 68.44% | 63.70% | 55.04% | 25.30% | 21.82% |
| Normalized Diluted EPS | 68.43% | 63.58% | 55.13% | 29.44% | 21.83% |
| Average Basic Shares Outstanding | 134.99% | 130.58% | 60.01% | 1.75% | 0.52% |
| Average Diluted Shares Outstanding | 134.99% | 130.58% | 60.01% | 1.75% | 0.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
